We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BD Expands BD MAX With IVDR-Approved VIASURE Tests in Europe
Read MoreHide Full Article
Key Takeaways
BDX received IVDR approval for two VIASURE assays, expanding BD MAX respiratory and STI testing in Europe.
New BD MAX tests detect COVID-19, flu, RSV, HSV-1/2 and syphilis using a fully automated system.
BDX says the expansion improves BD MAX utilization, customer reliance and recurring revenue growth.
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced the expansion of its respiratory and sexually transmitted infection (STI) diagnostics portfolio in Europe. This follows the In Vitro Diagnostic Medical Device Regulation (IVDR) certification of two VIASURE assays for the BD MAX System, designed by Certest Biotec to deliver fast and reliable results using a fully automated system. The latest development aims to expand BD’s molecular testing menu.
The newly approved tests include one respiratory virus test that can identify common breathing-related viruses at once — such as COVID-19, flu and RSV — by using a single nose swab and an HSV and syphilis test that detects the herpes simplex viruses (HSV-1 and HSV-2) and the syphilis (Treponema pallidum) bacteria, using swabs taken from infected areas on the mouth or genital area.
Per management, the expanded range of tests on the BD MAX system reflects the company’s focus on delivering clinically useful, specific molecular tests to BDX’s existing respiratory infections and sexually transmitted infections (STI) tests. Working with Certest Biotec supports the company’s goal to improve diagnostic solutions available on the BD MAX system to detect infections more quickly and thoroughly.
Likely Trend of BDX Stock Following the News
Following the announcement, shares of BDX had declined 0.4% at yesterday’s close. Over the past six months, shares of BD have climbed 16.3% compared with the industry’s 13.9% growth and the S&P 500’s 15.5% rise.
In the long run, the menu expansion supports BDX’s diagnostics growth strategy by increasing the utility and competitiveness of the BD MAX System in European markets. IVDR-approved assays deepen customer reliance, support recurring revenues and streamline workflows, contributing to the company’s Life Sciences segment’s growth.
BDX currently has a market capitalization of $57.34 billion.
Image Source: Zacks Investment Research
More on the BD MAX Menu Expansion
The BD MAX System is a lab machine that can test up to 24 patient samples at the same time. It supports many types of tests, including those for HAI, respiratory illnesses, enteric infections, sexually transmitted infections and women’s health tests. The combination of the BD MAX System with real-time PCR technology enables hospitals and laboratories to automate testing, prepare the sample to detect the result, improve patient care and optimize workflow efficiency.
The availability of IVDR-approved tests on an automated platform makes BDX more competitive and supports increased system utilization. The company’s collaboration with Certest Biotec since 2017 shows its open and partnership-driven approach to expanding BD’s test offerings in the molecular diagnostics range. Certest’s expertise in PCR assay development complements the company’s automated platform, accelerating the delivery of clinically useful tests to market and strengthening BD’s presence in European molecular diagnostics.
Industry Prospects Favoring the Molecular Diagnostics Market
Going by data provided by Precedence Research, the molecular diagnostics market is valued at $45.11 billion in 2025 and is expected to witness a CAGR of 3.8% through 2034. Factors like the rise in the geriatric population globally and an increase in the incidence of numerous diseases such as cancer, cardiovascular diseases, neurological disorders, diabetes and obesity, as well as various other diseases like HIV, HPV and STIs are shaping the market’s growth.
Other News
Recently, BDX announced that its BD Onclarity HPV Assay for the BD COR System and the BD Viper LT System has been approved by the World Health Organization and is considered high-quality and reliable, helping more women get tested for cervical cancer. Further on the news, the company’s Enteric Bacterial Panel and Enteric Bacterial Panel Plus for the BD COR System received U.S. FDA 510(k) approval and Conformité Européenne marking in the European Union.
BDX's Zacks Rank & Key Picks
Currently, BDX carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are BrightSpring Health Services, Inc. (BTSG - Free Report) , Cardinal Health (CAH - Free Report) and The Cooper Companies (COO - Free Report) .
BrightSpring Health Services, sporting a Zacks Rank #1 (Strong Buy) at present, reported third-quarter 2025 adjusted earnings per share (EPS) of 30 cents, which surpassed the Zacks Consensus Estimate by 11.11%. Revenues of $3.33 billion beat the Zacks Consensus Estimate by 5.46%. You can see the complete list of today’s Zacks #1 Rank stocks here.
BTSG has an estimated long-term earnings growth rate of 53.3% compared with the industry’s 15.5% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 45.05%.
Cardinal Health, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter fiscal 2026 adjusted EPS of $2.55, which surpassed the Zacks Consensus Estimate by 15.38%. Revenues of $64.0 billion beat the Zacks Consensus Estimate by 8.39%.
CAH has an estimated long-term earnings growth rate of 13.9% for 2025 compared with the industry’s 9.3% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 9.36%.
The Cooper Companies, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of $1.15, which surpassed the Zacks Consensus Estimate by 3.60%. Revenues of $1.06 billion beat the Zacks Consensus Estimate by 0.45%.
COO has an estimated long-term earnings growth rate of 7.8% compared with the industry’s 9.3% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 2.41%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BD Expands BD MAX With IVDR-Approved VIASURE Tests in Europe
Key Takeaways
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced the expansion of its respiratory and sexually transmitted infection (STI) diagnostics portfolio in Europe. This follows the In Vitro Diagnostic Medical Device Regulation (IVDR) certification of two VIASURE assays for the BD MAX System, designed by Certest Biotec to deliver fast and reliable results using a fully automated system. The latest development aims to expand BD’s molecular testing menu.
The newly approved tests include one respiratory virus test that can identify common breathing-related viruses at once — such as COVID-19, flu and RSV — by using a single nose swab and an HSV and syphilis test that detects the herpes simplex viruses (HSV-1 and HSV-2) and the syphilis (Treponema pallidum) bacteria, using swabs taken from infected areas on the mouth or genital area.
Per management, the expanded range of tests on the BD MAX system reflects the company’s focus on delivering clinically useful, specific molecular tests to BDX’s existing respiratory infections and sexually transmitted infections (STI) tests. Working with Certest Biotec supports the company’s goal to improve diagnostic solutions available on the BD MAX system to detect infections more quickly and thoroughly.
Likely Trend of BDX Stock Following the News
Following the announcement, shares of BDX had declined 0.4% at yesterday’s close. Over the past six months, shares of BD have climbed 16.3% compared with the industry’s 13.9% growth and the S&P 500’s 15.5% rise.
In the long run, the menu expansion supports BDX’s diagnostics growth strategy by increasing the utility and competitiveness of the BD MAX System in European markets. IVDR-approved assays deepen customer reliance, support recurring revenues and streamline workflows, contributing to the company’s Life Sciences segment’s growth.
BDX currently has a market capitalization of $57.34 billion.
Image Source: Zacks Investment Research
More on the BD MAX Menu Expansion
The BD MAX System is a lab machine that can test up to 24 patient samples at the same time. It supports many types of tests, including those for HAI, respiratory illnesses, enteric infections, sexually transmitted infections and women’s health tests. The combination of the BD MAX System with real-time PCR technology enables hospitals and laboratories to automate testing, prepare the sample to detect the result, improve patient care and optimize workflow efficiency.
The availability of IVDR-approved tests on an automated platform makes BDX more competitive and supports increased system utilization. The company’s collaboration with Certest Biotec since 2017 shows its open and partnership-driven approach to expanding BD’s test offerings in the molecular diagnostics range. Certest’s expertise in PCR assay development complements the company’s automated platform, accelerating the delivery of clinically useful tests to market and strengthening BD’s presence in European molecular diagnostics.
Industry Prospects Favoring the Molecular Diagnostics Market
Going by data provided by Precedence Research, the molecular diagnostics market is valued at $45.11 billion in 2025 and is expected to witness a CAGR of 3.8% through 2034. Factors like the rise in the geriatric population globally and an increase in the incidence of numerous diseases such as cancer, cardiovascular diseases, neurological disorders, diabetes and obesity, as well as various other diseases like HIV, HPV and STIs are shaping the market’s growth.
Other News
Recently, BDX announced that its BD Onclarity HPV Assay for the BD COR System and the BD Viper LT System has been approved by the World Health Organization and is considered high-quality and reliable, helping more women get tested for cervical cancer. Further on the news, the company’s Enteric Bacterial Panel and Enteric Bacterial Panel Plus for the BD COR System received U.S. FDA 510(k) approval and Conformité Européenne marking in the European Union.
BDX's Zacks Rank & Key Picks
Currently, BDX carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are BrightSpring Health Services, Inc. (BTSG - Free Report) , Cardinal Health (CAH - Free Report) and The Cooper Companies (COO - Free Report) .
BrightSpring Health Services, sporting a Zacks Rank #1 (Strong Buy) at present, reported third-quarter 2025 adjusted earnings per share (EPS) of 30 cents, which surpassed the Zacks Consensus Estimate by 11.11%. Revenues of $3.33 billion beat the Zacks Consensus Estimate by 5.46%. You can see the complete list of today’s Zacks #1 Rank stocks here.
BTSG has an estimated long-term earnings growth rate of 53.3% compared with the industry’s 15.5% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 45.05%.
Cardinal Health, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter fiscal 2026 adjusted EPS of $2.55, which surpassed the Zacks Consensus Estimate by 15.38%. Revenues of $64.0 billion beat the Zacks Consensus Estimate by 8.39%.
CAH has an estimated long-term earnings growth rate of 13.9% for 2025 compared with the industry’s 9.3% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 9.36%.
The Cooper Companies, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of $1.15, which surpassed the Zacks Consensus Estimate by 3.60%. Revenues of $1.06 billion beat the Zacks Consensus Estimate by 0.45%.
COO has an estimated long-term earnings growth rate of 7.8% compared with the industry’s 9.3% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 2.41%.